DDInter717 DDInter1376
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Fenfluramine {u} may lead to a major life threatening interaction when taken with {v} Phendimetrazine
Fenfluramine {u} may lead to a major life threatening interaction when taken with {v} Fluvoxamine
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Fenfluramine may lead to a major life threatening interaction when taken with Phendimetrazine
Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine